DRUGS MADE IN AMERICA ACQUIS (DMAA) Forecast, Price Target & Analyst Ratings

NASDAQ:DMAA • KYG2847J1040

10.47 USD
+0.01 (+0.1%)
Last: Mar 4, 2026, 08:20 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for DRUGS MADE IN AMERICA ACQUIS (DMAA).

Forecast Snapshot

Consensus Price Target

Price Target
N/A
N/A

Next Earnings Forecast

Earnings Estimate
Release DateMar 18, 2026

ChartMill Buy Consensus

Rating
%
Weighted Analyst Rating Score

Price Target Details & History

Consensus Price Target and Range

Mean target
N/A
Upside
N/A
From current price of $10.47 to mean target of N/A, Based on analyst forecasts
Low
N/A
Median
N/A
High
N/A

Price Target Revisions

1 Month
N/A
3 Months
N/A

Price Target Summary

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus
%
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Next Earnings Forecast Details

Next Earnings Details

Release DateMar 18, 2026

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024
Revenue
YoY % growth
DMAA revenue by date.DMAA revenue by date.
EBITDA
YoY % growth
DMAA ebitda by date.DMAA ebitda by date.
N/AN/A
EBIT
YoY % growth
DMAA ebit by date.DMAA ebit by date.
-279.9K
Operating Margin
DMAA operating margin by date.DMAA operating margin by date.
N/AN/A
EPS
YoY % growth
DMAA eps by date.DMAA eps by date.
N/AN/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
N/A
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

DRUGS MADE IN AMERICA ACQUIS / DMAA Forecast FAQ

What is the next earnings date for DMAA stock?

DRUGS MADE IN AMERICA ACQUIS (DMAA) will report earnings on 2026-03-18.